Login to Your Account



Merck Unwilling To Modify Colorectal Trial For ImClone

By Brady Huggett


Friday, May 17, 2002
The rumor mill churned out bad news for ImClone Systems Inc. Thursday when a German publication reported that Merck KGaA would not share its much-needed colorectal cancer trial data with ImClone for Erbitux. Throw in the release of first-quarter earnings that showed a greater-than-expected loss per share, and ImClone began Thursday with an 18 percent stock drop. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription